Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Leukemia, Lymphocytic, Chronic, B-Cell | 82 | 2023 | 2390 | 12.560 |
Why?
|
Antineoplastic Agents | 92 | 2023 | 14289 | 4.250 |
Why?
|
Apoptosis | 69 | 2023 | 7591 | 4.210 |
Why?
|
Arabinonucleosides | 37 | 2022 | 437 | 4.080 |
Why?
|
Proto-Oncogene Proteins c-pim-1 | 8 | 2016 | 45 | 3.060 |
Why?
|
Myeloid Cell Leukemia Sequence 1 Protein | 18 | 2023 | 275 | 3.030 |
Why?
|
2-Chloroadenosine | 13 | 2023 | 37 | 3.000 |
Why?
|
Purines | 11 | 2017 | 273 | 2.900 |
Why?
|
Multiple Myeloma | 24 | 2017 | 2138 | 2.720 |
Why?
|
Lymphoma, Mantle-Cell | 10 | 2021 | 713 | 2.710 |
Why?
|
Vidarabine | 43 | 2021 | 1341 | 2.700 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 22 | 2023 | 1493 | 2.490 |
Why?
|
Protein Kinase Inhibitors | 22 | 2022 | 4757 | 2.300 |
Why?
|
Cytarabine | 47 | 2018 | 1973 | 2.220 |
Why?
|
Antimetabolites, Antineoplastic | 25 | 2015 | 1299 | 2.140 |
Why?
|
Hydrazones | 4 | 2016 | 42 | 2.100 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 53 | 2021 | 15862 | 1.960 |
Why?
|
Adenine | 15 | 2021 | 631 | 1.880 |
Why?
|
Pyrazoles | 12 | 2021 | 1471 | 1.830 |
Why?
|
Leukemia | 21 | 2020 | 1635 | 1.820 |
Why?
|
Adenosine | 9 | 2012 | 289 | 1.790 |
Why?
|
Adenosine Triphosphate | 20 | 2019 | 571 | 1.770 |
Why?
|
Isoquinolines | 4 | 2017 | 116 | 1.770 |
Why?
|
Purine-Nucleoside Phosphorylase | 8 | 2010 | 46 | 1.750 |
Why?
|
Purine Nucleosides | 10 | 2013 | 48 | 1.750 |
Why?
|
Piperidines | 19 | 2021 | 1035 | 1.720 |
Why?
|
Pyrimidinones | 8 | 2013 | 314 | 1.670 |
Why?
|
Pyrimidines | 16 | 2021 | 3518 | 1.660 |
Why?
|
Sulfonamides | 13 | 2021 | 1823 | 1.620 |
Why?
|
Piperazines | 10 | 2020 | 2101 | 1.500 |
Why?
|
Tumor Cells, Cultured | 38 | 2019 | 5395 | 1.500 |
Why?
|
Lymphocytes | 17 | 2019 | 1234 | 1.460 |
Why?
|
Pyridazines | 5 | 2013 | 293 | 1.450 |
Why?
|
Ataxia Telangiectasia Mutated Proteins | 3 | 2021 | 430 | 1.430 |
Why?
|
Quinazolinones | 4 | 2017 | 51 | 1.400 |
Why?
|
Deoxyadenosines | 4 | 2017 | 42 | 1.400 |
Why?
|
Signal Transduction | 27 | 2022 | 11965 | 1.360 |
Why?
|
Humans | 257 | 2024 | 261506 | 1.350 |
Why?
|
Deoxycytidine | 16 | 2007 | 1353 | 1.350 |
Why?
|
Leukemia, Myeloid, Acute | 39 | 2023 | 6915 | 1.350 |
Why?
|
Proto-Oncogene Proteins c-met | 7 | 2017 | 419 | 1.340 |
Why?
|
Bridged Bicyclo Compounds, Heterocyclic | 9 | 2021 | 923 | 1.330 |
Why?
|
Gene Expression Regulation, Leukemic | 6 | 2020 | 560 | 1.320 |
Why?
|
Cell Line, Tumor | 46 | 2023 | 14551 | 1.320 |
Why?
|
Caspases | 11 | 2016 | 661 | 1.320 |
Why?
|
Adenine Nucleotides | 19 | 2017 | 351 | 1.290 |
Why?
|
Cell Survival | 21 | 2019 | 3045 | 1.230 |
Why?
|
Arabinonucleotides | 17 | 2008 | 71 | 1.200 |
Why?
|
Proto-Oncogene Proteins | 9 | 2017 | 2488 | 1.180 |
Why?
|
Stromal Cells | 8 | 2017 | 825 | 1.170 |
Why?
|
Imidazoles | 5 | 2013 | 999 | 1.170 |
Why?
|
Bone Marrow Cells | 7 | 2019 | 943 | 1.150 |
Why?
|
Biphenyl Compounds | 6 | 2022 | 194 | 1.120 |
Why?
|
Transcription, Genetic | 16 | 2013 | 3154 | 1.100 |
Why?
|
Primary Cell Culture | 4 | 2020 | 208 | 1.080 |
Why?
|
Gossypol | 3 | 2012 | 28 | 1.080 |
Why?
|
Nitrogen Mustard Compounds | 5 | 2018 | 73 | 1.080 |
Why?
|
Drug Screening Assays, Antitumor | 12 | 2020 | 566 | 1.080 |
Why?
|
Receptors, Antigen, B-Cell | 5 | 2022 | 171 | 1.070 |
Why?
|
Dose-Response Relationship, Drug | 29 | 2019 | 4938 | 1.060 |
Why?
|
Reactive Oxygen Species | 6 | 2020 | 987 | 1.050 |
Why?
|
Protein Biosynthesis | 6 | 2016 | 889 | 1.030 |
Why?
|
Bendamustine Hydrochloride | 6 | 2017 | 107 | 1.030 |
Why?
|
Prodrugs | 8 | 2014 | 217 | 1.010 |
Why?
|
Phosphorylation | 29 | 2021 | 4804 | 0.990 |
Why?
|
Ribonucleotide Reductases | 6 | 2013 | 51 | 0.960 |
Why?
|
Arabinofuranosylcytosine Triphosphate | 18 | 2007 | 75 | 0.950 |
Why?
|
Enzyme Inhibitors | 9 | 2023 | 1879 | 0.920 |
Why?
|
Pyrazines | 3 | 2017 | 495 | 0.920 |
Why?
|
Endoplasmic Reticulum Stress | 2 | 2016 | 204 | 0.910 |
Why?
|
Proteomics | 6 | 2017 | 1380 | 0.910 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 15 | 2022 | 2796 | 0.900 |
Why?
|
Oxidative Phosphorylation | 4 | 2021 | 253 | 0.880 |
Why?
|
Apoptosis Regulatory Proteins | 4 | 2023 | 621 | 0.860 |
Why?
|
B-Lymphocytes | 6 | 2020 | 1294 | 0.850 |
Why?
|
Animals | 62 | 2023 | 59536 | 0.850 |
Why?
|
Autophagy | 5 | 2017 | 927 | 0.840 |
Why?
|
Drug Resistance, Neoplasm | 23 | 2017 | 5178 | 0.830 |
Why?
|
Glycolysis | 4 | 2019 | 519 | 0.820 |
Why?
|
Cell Separation | 4 | 2019 | 612 | 0.820 |
Why?
|
T-Lymphocytes | 12 | 2023 | 3869 | 0.810 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 11 | 2014 | 2527 | 0.790 |
Why?
|
Ionophores | 1 | 2020 | 22 | 0.770 |
Why?
|
Drug Synergism | 13 | 2020 | 1313 | 0.770 |
Why?
|
Ataxia Telangiectasia | 1 | 2021 | 62 | 0.760 |
Why?
|
Flow Cytometry | 10 | 2019 | 3033 | 0.760 |
Why?
|
RNA, Neoplasm | 9 | 2012 | 771 | 0.750 |
Why?
|
Guanosine Triphosphate | 9 | 2008 | 90 | 0.740 |
Why?
|
Thiazolidines | 2 | 2018 | 16 | 0.730 |
Why?
|
Cell Proliferation | 20 | 2021 | 7226 | 0.730 |
Why?
|
RNA, Messenger | 20 | 2016 | 6150 | 0.730 |
Why?
|
Tumor Microenvironment | 6 | 2022 | 2864 | 0.730 |
Why?
|
Spiro Compounds | 1 | 2020 | 58 | 0.720 |
Why?
|
Receptors, Growth Factor | 3 | 2008 | 157 | 0.710 |
Why?
|
Proto-Oncogene Proteins c-akt | 6 | 2016 | 2054 | 0.700 |
Why?
|
Naphthalenes | 1 | 2020 | 83 | 0.700 |
Why?
|
Polynucleotide Adenylyltransferase | 2 | 2009 | 10 | 0.690 |
Why?
|
Metabolic Flux Analysis | 1 | 2019 | 27 | 0.680 |
Why?
|
Mitochondria | 6 | 2020 | 1282 | 0.670 |
Why?
|
Leukocytes, Mononuclear | 6 | 2020 | 709 | 0.670 |
Why?
|
Heat-Shock Proteins | 2 | 2011 | 311 | 0.660 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 14 | 2019 | 3639 | 0.660 |
Why?
|
TOR Serine-Threonine Kinases | 3 | 2016 | 1546 | 0.660 |
Why?
|
Mice | 28 | 2023 | 34495 | 0.650 |
Why?
|
Pyrrolidinones | 2 | 2017 | 61 | 0.650 |
Why?
|
Caspase 3 | 4 | 2016 | 471 | 0.650 |
Why?
|
ZAP-70 Protein-Tyrosine Kinase | 2 | 2017 | 102 | 0.650 |
Why?
|
Drug Design | 4 | 2018 | 375 | 0.640 |
Why?
|
Neoplasms | 22 | 2018 | 15193 | 0.640 |
Why?
|
Oxidative Stress | 4 | 2020 | 1129 | 0.640 |
Why?
|
Zinc | 2 | 2016 | 188 | 0.630 |
Why?
|
Gene Expression Regulation, Neoplastic | 9 | 2019 | 8873 | 0.630 |
Why?
|
Coculture Techniques | 7 | 2019 | 626 | 0.630 |
Why?
|
Lymphoma, B-Cell | 2 | 2016 | 895 | 0.620 |
Why?
|
Biological Assay | 1 | 2019 | 177 | 0.620 |
Why?
|
Cell Cycle | 16 | 2016 | 2084 | 0.610 |
Why?
|
Drug Evaluation, Preclinical | 8 | 2016 | 503 | 0.600 |
Why?
|
Leukemia-Lymphoma, Adult T-Cell | 3 | 2006 | 65 | 0.600 |
Why?
|
AMP-Activated Protein Kinases | 2 | 2017 | 413 | 0.600 |
Why?
|
Hematologic Neoplasms | 10 | 2018 | 1870 | 0.590 |
Why?
|
Proteome | 3 | 2017 | 561 | 0.590 |
Why?
|
Benzamides | 4 | 2017 | 1832 | 0.580 |
Why?
|
Oligopeptides | 2 | 2016 | 429 | 0.570 |
Why?
|
Cell Death | 10 | 2014 | 671 | 0.570 |
Why?
|
DNA Damage | 8 | 2020 | 1954 | 0.570 |
Why?
|
Vidarabine Phosphate | 7 | 2002 | 50 | 0.560 |
Why?
|
Caveolin 1 | 1 | 2017 | 204 | 0.560 |
Why?
|
RNA | 8 | 2016 | 1013 | 0.560 |
Why?
|
Receptor Protein-Tyrosine Kinases | 3 | 2015 | 661 | 0.540 |
Why?
|
Energy Metabolism | 4 | 2019 | 992 | 0.540 |
Why?
|
Health Resources | 1 | 2017 | 168 | 0.530 |
Why?
|
DNA | 16 | 2017 | 2693 | 0.520 |
Why?
|
Quinolines | 2 | 2017 | 383 | 0.520 |
Why?
|
Chelating Agents | 1 | 2016 | 127 | 0.520 |
Why?
|
Hydrogen Peroxide | 5 | 2018 | 217 | 0.520 |
Why?
|
Caspases, Effector | 1 | 2014 | 5 | 0.520 |
Why?
|
Ribosomal Protein S6 Kinases | 1 | 2015 | 116 | 0.520 |
Why?
|
Protein Kinases | 4 | 2021 | 874 | 0.520 |
Why?
|
B-Cell Activating Factor | 3 | 2015 | 25 | 0.520 |
Why?
|
Deoxycytidine Kinase | 7 | 2013 | 27 | 0.510 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2020 | 1226 | 0.510 |
Why?
|
Monocytes | 1 | 2019 | 788 | 0.500 |
Why?
|
Fibroblasts | 6 | 2020 | 1682 | 0.500 |
Why?
|
bcl-2-Associated X Protein | 2 | 2012 | 367 | 0.490 |
Why?
|
Guanosine | 3 | 2010 | 22 | 0.490 |
Why?
|
Clinical Trials, Phase I as Topic | 8 | 2017 | 604 | 0.490 |
Why?
|
Cladribine | 9 | 2013 | 233 | 0.480 |
Why?
|
Lactams, Macrocyclic | 2 | 2011 | 90 | 0.480 |
Why?
|
Harringtonines | 2 | 2014 | 92 | 0.480 |
Why?
|
Leukemia, Lymphoid | 2 | 2005 | 276 | 0.480 |
Why?
|
Benzoquinones | 2 | 2011 | 108 | 0.480 |
Why?
|
Mitochondrial Proteins | 1 | 2016 | 369 | 0.470 |
Why?
|
Blood Specimen Collection | 1 | 2014 | 93 | 0.470 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 2 | 2023 | 1664 | 0.470 |
Why?
|
Deoxyadenine Nucleotides | 3 | 2008 | 24 | 0.470 |
Why?
|
Pyrroles | 3 | 2006 | 576 | 0.460 |
Why?
|
Drug Administration Schedule | 23 | 2018 | 3472 | 0.460 |
Why?
|
Drug Delivery Systems | 2 | 2015 | 669 | 0.460 |
Why?
|
Cells, Cultured | 10 | 2017 | 5637 | 0.450 |
Why?
|
Nitrophenols | 3 | 2020 | 92 | 0.450 |
Why?
|
Antineoplastic Agents, Alkylating | 5 | 2019 | 588 | 0.450 |
Why?
|
Chromatography, High Pressure Liquid | 6 | 2009 | 548 | 0.440 |
Why?
|
Aged | 52 | 2022 | 70117 | 0.440 |
Why?
|
DNA, Neoplasm | 8 | 2009 | 1910 | 0.440 |
Why?
|
Boronic Acids | 4 | 2018 | 362 | 0.440 |
Why?
|
Intracellular Signaling Peptides and Proteins | 3 | 2016 | 1265 | 0.440 |
Why?
|
Male | 64 | 2021 | 123000 | 0.440 |
Why?
|
bcl-2 Homologous Antagonist-Killer Protein | 1 | 2012 | 72 | 0.430 |
Why?
|
Phosphatidylinositol 3-Kinases | 3 | 2016 | 1678 | 0.430 |
Why?
|
Chemokine CXCL2 | 1 | 2012 | 35 | 0.430 |
Why?
|
Biomedical Research | 3 | 2024 | 806 | 0.430 |
Why?
|
Middle Aged | 58 | 2022 | 86204 | 0.420 |
Why?
|
Protein Stability | 2 | 2023 | 370 | 0.420 |
Why?
|
Oligodeoxyribonucleotides | 2 | 2011 | 261 | 0.410 |
Why?
|
Adult | 54 | 2022 | 77950 | 0.410 |
Why?
|
Medical Oncology | 3 | 2017 | 1423 | 0.400 |
Why?
|
Chemokine CCL2 | 1 | 2012 | 203 | 0.400 |
Why?
|
Thymine Nucleotides | 1 | 2010 | 17 | 0.390 |
Why?
|
DNA Repair | 5 | 2013 | 1872 | 0.390 |
Why?
|
Lymphoma | 4 | 2013 | 1467 | 0.380 |
Why?
|
Thymidine | 1 | 2010 | 155 | 0.380 |
Why?
|
Immunoblotting | 9 | 2017 | 886 | 0.380 |
Why?
|
Female | 59 | 2021 | 141928 | 0.380 |
Why?
|
Neoplasm Proteins | 9 | 2014 | 3230 | 0.380 |
Why?
|
Fusion Proteins, bcr-abl | 3 | 2014 | 1094 | 0.380 |
Why?
|
Receptors, Glucocorticoid | 2 | 2008 | 192 | 0.370 |
Why?
|
Blotting, Western | 9 | 2016 | 3536 | 0.370 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 3 | 2017 | 521 | 0.370 |
Why?
|
Succinic Acid | 1 | 2010 | 23 | 0.370 |
Why?
|
Oxygen Consumption | 3 | 2019 | 401 | 0.370 |
Why?
|
Fumarates | 1 | 2010 | 30 | 0.360 |
Why?
|
HSP90 Heat-Shock Proteins | 1 | 2011 | 196 | 0.360 |
Why?
|
Blast Crisis | 6 | 2012 | 557 | 0.360 |
Why?
|
In Vitro Techniques | 8 | 2015 | 1618 | 0.360 |
Why?
|
Jurkat Cells | 3 | 2020 | 311 | 0.360 |
Why?
|
Prognosis | 15 | 2021 | 21713 | 0.360 |
Why?
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2023 | 305 | 0.360 |
Why?
|
ATP Synthetase Complexes | 1 | 2009 | 5 | 0.350 |
Why?
|
Down-Regulation | 4 | 2009 | 2074 | 0.350 |
Why?
|
Infusions, Intravenous | 13 | 2006 | 1382 | 0.350 |
Why?
|
Lymphoid Tissue | 1 | 2009 | 95 | 0.350 |
Why?
|
Clinical Trials as Topic | 15 | 2017 | 3719 | 0.350 |
Why?
|
Bone Marrow | 5 | 2019 | 2358 | 0.340 |
Why?
|
Deoxyguanosine | 4 | 2007 | 37 | 0.340 |
Why?
|
Clinical Trials, Phase II as Topic | 6 | 2017 | 665 | 0.340 |
Why?
|
CD40 Ligand | 1 | 2009 | 115 | 0.340 |
Why?
|
CD40 Antigens | 1 | 2009 | 104 | 0.340 |
Why?
|
BH3 Interacting Domain Death Agonist Protein | 1 | 2008 | 37 | 0.330 |
Why?
|
Real-Time Polymerase Chain Reaction | 3 | 2019 | 1217 | 0.330 |
Why?
|
Embryo, Mammalian | 3 | 2017 | 741 | 0.330 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2013 | 482 | 0.330 |
Why?
|
Deoxyguanine Nucleotides | 4 | 2013 | 21 | 0.330 |
Why?
|
Metabolic Networks and Pathways | 4 | 2019 | 336 | 0.320 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2010 | 460 | 0.320 |
Why?
|
Cell Line | 8 | 2019 | 5114 | 0.320 |
Why?
|
Protein-Tyrosine Kinases | 5 | 2017 | 1756 | 0.320 |
Why?
|
Leukemia, Prolymphocytic, T-Cell | 1 | 2008 | 43 | 0.310 |
Why?
|
Polyadenylation | 1 | 2008 | 70 | 0.310 |
Why?
|
Chemokine CCL4 | 3 | 2017 | 63 | 0.310 |
Why?
|
Chemokine CCL3 | 3 | 2017 | 63 | 0.310 |
Why?
|
Receptor, Notch1 | 1 | 2009 | 218 | 0.300 |
Why?
|
Substrate Specificity | 6 | 2009 | 549 | 0.300 |
Why?
|
Cyclin E | 1 | 2009 | 267 | 0.300 |
Why?
|
8-Bromo Cyclic Adenosine Monophosphate | 2 | 2010 | 28 | 0.300 |
Why?
|
Enzyme Activation | 6 | 2015 | 1764 | 0.300 |
Why?
|
Molecular Structure | 6 | 2010 | 515 | 0.300 |
Why?
|
B-Cell Activation Factor Receptor | 1 | 2006 | 24 | 0.290 |
Why?
|
Nucleotides | 6 | 2023 | 164 | 0.290 |
Why?
|
bcl-X Protein | 3 | 2017 | 196 | 0.290 |
Why?
|
Antioxidants | 3 | 2020 | 507 | 0.280 |
Why?
|
Idarubicin | 3 | 2017 | 446 | 0.280 |
Why?
|
Kinetics | 10 | 2005 | 2049 | 0.270 |
Why?
|
Gene Expression | 5 | 2017 | 3570 | 0.270 |
Why?
|
Plant Proteins | 1 | 2006 | 133 | 0.270 |
Why?
|
Nucleosides | 5 | 2008 | 60 | 0.270 |
Why?
|
Salvage Therapy | 4 | 2011 | 2054 | 0.270 |
Why?
|
Mutation | 9 | 2022 | 15179 | 0.270 |
Why?
|
Drugs, Investigational | 1 | 2006 | 135 | 0.270 |
Why?
|
Uncoupling Agents | 2 | 2019 | 15 | 0.260 |
Why?
|
Cell Communication | 3 | 2017 | 509 | 0.260 |
Why?
|
DNA Replication | 6 | 1996 | 744 | 0.260 |
Why?
|
RNA Polymerase II | 4 | 2010 | 182 | 0.260 |
Why?
|
Intercalating Agents | 2 | 2017 | 29 | 0.260 |
Why?
|
Tumor Suppressor Protein p53 | 4 | 2021 | 3552 | 0.260 |
Why?
|
Leukemia, Myeloid | 5 | 2009 | 941 | 0.250 |
Why?
|
Xenograft Model Antitumor Assays | 6 | 2019 | 3821 | 0.250 |
Why?
|
Lymphoma, Non-Hodgkin | 3 | 2022 | 1039 | 0.250 |
Why?
|
Treatment Outcome | 25 | 2018 | 32848 | 0.250 |
Why?
|
Intracellular Space | 2 | 2017 | 77 | 0.240 |
Why?
|
Oxidoreductases Acting on CH-CH Group Donors | 1 | 2023 | 12 | 0.240 |
Why?
|
Thiosemicarbazones | 1 | 2003 | 23 | 0.240 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2008 | 852 | 0.240 |
Why?
|
Maximum Tolerated Dose | 7 | 2018 | 1290 | 0.240 |
Why?
|
Gene Expression Profiling | 7 | 2019 | 5159 | 0.240 |
Why?
|
Societies, Scientific | 2 | 2014 | 74 | 0.240 |
Why?
|
Phosphotransferases (Alcohol Group Acceptor) | 2 | 2002 | 129 | 0.230 |
Why?
|
Lymphoma, T-Cell | 1 | 2006 | 361 | 0.230 |
Why?
|
Biomarkers | 4 | 2019 | 5047 | 0.230 |
Why?
|
Biotransformation | 6 | 2002 | 93 | 0.220 |
Why?
|
X-Linked Inhibitor of Apoptosis Protein | 3 | 2016 | 119 | 0.220 |
Why?
|
Models, Chemical | 4 | 2009 | 186 | 0.220 |
Why?
|
K562 Cells | 5 | 2012 | 338 | 0.220 |
Why?
|
Molecular Targeted Therapy | 4 | 2014 | 2330 | 0.220 |
Why?
|
RNA Viruses | 1 | 2022 | 43 | 0.220 |
Why?
|
Time Factors | 14 | 2014 | 12926 | 0.220 |
Why?
|
Clinical Studies as Topic | 1 | 2022 | 19 | 0.220 |
Why?
|
Mentoring | 1 | 2024 | 87 | 0.220 |
Why?
|
Administration, Oral | 4 | 2021 | 1544 | 0.210 |
Why?
|
Promoter Regions, Genetic | 2 | 2008 | 3101 | 0.210 |
Why?
|
Cell Growth Processes | 3 | 2013 | 342 | 0.210 |
Why?
|
Base Sequence | 9 | 2017 | 4917 | 0.210 |
Why?
|
Membrane Potential, Mitochondrial | 2 | 2020 | 133 | 0.210 |
Why?
|
Clone Cells | 1 | 2023 | 555 | 0.200 |
Why?
|
Immunotherapy, Adoptive | 2 | 2022 | 1763 | 0.200 |
Why?
|
Acute Disease | 6 | 2013 | 2422 | 0.200 |
Why?
|
Leukemia, T-Cell | 3 | 2009 | 87 | 0.200 |
Why?
|
Ubiquitin Thiolesterase | 1 | 2023 | 216 | 0.200 |
Why?
|
Bortezomib | 2 | 2015 | 543 | 0.200 |
Why?
|
Pyrimidine Nucleosides | 1 | 2001 | 7 | 0.200 |
Why?
|
Leukemia, Prolymphocytic | 1 | 2001 | 51 | 0.200 |
Why?
|
Pyridines | 2 | 2009 | 1244 | 0.200 |
Why?
|
Pentostatin | 2 | 2002 | 119 | 0.200 |
Why?
|
Granulocyte Colony-Stimulating Factor | 5 | 2008 | 749 | 0.200 |
Why?
|
Remission Induction | 13 | 2022 | 3569 | 0.190 |
Why?
|
Protein Conformation | 3 | 2016 | 1258 | 0.190 |
Why?
|
Immunoglobulin Variable Region | 1 | 2021 | 173 | 0.190 |
Why?
|
Myelodysplastic Syndromes | 7 | 2012 | 2979 | 0.190 |
Why?
|
Inhibitory Concentration 50 | 2 | 2015 | 289 | 0.190 |
Why?
|
Aged, 80 and over | 17 | 2021 | 29902 | 0.190 |
Why?
|
Models, Biological | 5 | 2016 | 3254 | 0.190 |
Why?
|
MicroRNAs | 2 | 2011 | 2947 | 0.180 |
Why?
|
Immunoglobulin Heavy Chains | 1 | 2021 | 247 | 0.180 |
Why?
|
Cell Division | 6 | 2008 | 2489 | 0.180 |
Why?
|
Drug Therapy, Combination | 4 | 2015 | 2315 | 0.180 |
Why?
|
Oxazoles | 2 | 2010 | 60 | 0.180 |
Why?
|
Hydroxyurea | 2 | 1998 | 204 | 0.180 |
Why?
|
Hydrogen-Ion Concentration | 1 | 2020 | 585 | 0.170 |
Why?
|
Immunologic Factors | 2 | 2019 | 649 | 0.170 |
Why?
|
RNA, Small Interfering | 3 | 2012 | 2216 | 0.170 |
Why?
|
Cytosol | 3 | 2011 | 238 | 0.170 |
Why?
|
Flavonoids | 4 | 2009 | 188 | 0.170 |
Why?
|
Centrifugation, Density Gradient | 1 | 2019 | 124 | 0.170 |
Why?
|
Kelch-Like ECH-Associated Protein 1 | 1 | 2019 | 104 | 0.170 |
Why?
|
DNA Polymerase I | 2 | 2002 | 27 | 0.170 |
Why?
|
Cytidine Triphosphate | 1 | 2018 | 9 | 0.170 |
Why?
|
Melphalan | 2 | 2015 | 834 | 0.170 |
Why?
|
Protein Binding | 5 | 2016 | 3438 | 0.170 |
Why?
|
Drug Monitoring | 1 | 2021 | 333 | 0.170 |
Why?
|
Uridine Triphosphate | 1 | 1998 | 19 | 0.170 |
Why?
|
Biomarkers, Tumor | 4 | 2021 | 10331 | 0.170 |
Why?
|
Neoplastic Stem Cells | 2 | 1997 | 1443 | 0.160 |
Why?
|
HeLa Cells | 2 | 2021 | 1643 | 0.160 |
Why?
|
Mice, Inbred NOD | 3 | 2021 | 905 | 0.160 |
Why?
|
Lysosomes | 1 | 2020 | 347 | 0.160 |
Why?
|
Histones | 2 | 2020 | 1466 | 0.160 |
Why?
|
Recurrence | 11 | 2018 | 4758 | 0.160 |
Why?
|
Cell Count | 1 | 2019 | 508 | 0.160 |
Why?
|
Drug Approval | 3 | 2014 | 178 | 0.150 |
Why?
|
Indolequinones | 1 | 2017 | 4 | 0.150 |
Why?
|
Class Ib Phosphatidylinositol 3-Kinase | 1 | 2017 | 15 | 0.150 |
Why?
|
Ribonucleotides | 1 | 2017 | 52 | 0.150 |
Why?
|
Molecular Sequence Data | 7 | 2011 | 6089 | 0.150 |
Why?
|
Benzene Derivatives | 1 | 2017 | 23 | 0.150 |
Why?
|
Glutamine | 1 | 2019 | 299 | 0.150 |
Why?
|
Enzyme Induction | 1 | 2017 | 249 | 0.150 |
Why?
|
Protein Structure, Tertiary | 3 | 2010 | 1487 | 0.150 |
Why?
|
DNA Polymerase II | 2 | 2002 | 59 | 0.150 |
Why?
|
Chemotaxis | 2 | 2015 | 138 | 0.150 |
Why?
|
NF-E2-Related Factor 2 | 1 | 2019 | 249 | 0.150 |
Why?
|
Recombinant Fusion Proteins | 3 | 2010 | 1555 | 0.150 |
Why?
|
Child | 16 | 2018 | 29154 | 0.150 |
Why?
|
Erlotinib Hydrochloride | 1 | 2018 | 388 | 0.150 |
Why?
|
Cellular Reprogramming | 1 | 2019 | 189 | 0.150 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 4 | 2021 | 5319 | 0.150 |
Why?
|
Mice, Knockout | 2 | 2017 | 5710 | 0.140 |
Why?
|
International Agencies | 2 | 2014 | 107 | 0.140 |
Why?
|
Leukocytes | 1 | 2019 | 422 | 0.140 |
Why?
|
DNA Ligases | 1 | 1996 | 63 | 0.140 |
Why?
|
Ubiquitinated Proteins | 1 | 2016 | 9 | 0.140 |
Why?
|
Transcription Factor CHOP | 1 | 2016 | 25 | 0.140 |
Why?
|
Mice, SCID | 4 | 2019 | 1869 | 0.140 |
Why?
|
Triterpenes | 1 | 2016 | 61 | 0.140 |
Why?
|
HL-60 Cells | 2 | 2015 | 302 | 0.140 |
Why?
|
Phosphoproteins | 2 | 2012 | 1152 | 0.140 |
Why?
|
HEK293 Cells | 1 | 2020 | 1489 | 0.140 |
Why?
|
Oxidation-Reduction | 2 | 2021 | 717 | 0.140 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 1994 | 408 | 0.140 |
Why?
|
Poly (ADP-Ribose) Polymerase-1 | 1 | 2016 | 170 | 0.140 |
Why?
|
DNA Primers | 3 | 2009 | 1399 | 0.140 |
Why?
|
Rats | 3 | 2002 | 6086 | 0.140 |
Why?
|
Phosphonoacetic Acid | 1 | 2015 | 18 | 0.130 |
Why?
|
Neoplastic Cells, Circulating | 2 | 2015 | 607 | 0.130 |
Why?
|
Fluorescent Antibody Technique | 2 | 2016 | 1062 | 0.130 |
Why?
|
Cyclin A | 1 | 2015 | 47 | 0.130 |
Why?
|
Cyclin-Dependent Kinase 2 | 2 | 2015 | 249 | 0.130 |
Why?
|
Pilot Projects | 3 | 2018 | 2803 | 0.130 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2021 | 854 | 0.130 |
Why?
|
Hematologic Diseases | 2 | 1994 | 242 | 0.130 |
Why?
|
Lung Neoplasms | 6 | 2021 | 11538 | 0.130 |
Why?
|
Adaptor Proteins, Signal Transducing | 2 | 2012 | 1439 | 0.130 |
Why?
|
Thiazoles | 2 | 2010 | 726 | 0.130 |
Why?
|
Adoptive Transfer | 1 | 2017 | 446 | 0.130 |
Why?
|
Aspartic Acid | 1 | 2015 | 126 | 0.130 |
Why?
|
Cell Nucleus | 1 | 2020 | 1620 | 0.130 |
Why?
|
Immunoprecipitation | 1 | 2016 | 591 | 0.130 |
Why?
|
Protein Domains | 1 | 2016 | 314 | 0.130 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2016 | 447 | 0.130 |
Why?
|
Polymorphism, Single Nucleotide | 4 | 2018 | 4549 | 0.130 |
Why?
|
Young Adult | 11 | 2022 | 21445 | 0.130 |
Why?
|
Gene Expression Regulation, Enzymologic | 2 | 2014 | 703 | 0.120 |
Why?
|
Caspase 9 | 3 | 2011 | 189 | 0.120 |
Why?
|
Deoxyribonucleotides | 2 | 1991 | 21 | 0.120 |
Why?
|
Thiourea | 1 | 2013 | 18 | 0.120 |
Why?
|
Waldenstrom Macroglobulinemia | 3 | 1994 | 273 | 0.120 |
Why?
|
src-Family Kinases | 1 | 2016 | 478 | 0.120 |
Why?
|
Cross-Linking Reagents | 1 | 2014 | 153 | 0.120 |
Why?
|
Ribonucleoside Diphosphate Reductase | 1 | 2013 | 29 | 0.120 |
Why?
|
S Phase | 3 | 2002 | 281 | 0.120 |
Why?
|
MAP Kinase Signaling System | 2 | 2016 | 848 | 0.120 |
Why?
|
Apoptotic Protease-Activating Factor 1 | 2 | 2011 | 38 | 0.120 |
Why?
|
Adolescent | 16 | 2022 | 31252 | 0.120 |
Why?
|
Proteasome Inhibitors | 1 | 2015 | 231 | 0.120 |
Why?
|
Indoles | 1 | 2019 | 1009 | 0.120 |
Why?
|
Protein Precursors | 1 | 2014 | 240 | 0.110 |
Why?
|
Pancreatic Neoplasms | 1 | 2010 | 5061 | 0.110 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2016 | 589 | 0.110 |
Why?
|
Cyclin D1 | 2 | 2012 | 576 | 0.110 |
Why?
|
Cell Cycle Proteins | 2 | 2012 | 2045 | 0.110 |
Why?
|
Metallocenes | 1 | 2012 | 3 | 0.110 |
Why?
|
Child, Preschool | 10 | 2018 | 16273 | 0.110 |
Why?
|
Regression Analysis | 1 | 2016 | 1546 | 0.110 |
Why?
|
Glucosephosphate Dehydrogenase | 1 | 2012 | 25 | 0.110 |
Why?
|
Sequence Analysis, DNA | 1 | 2020 | 2483 | 0.110 |
Why?
|
Ferrous Compounds | 1 | 2012 | 13 | 0.110 |
Why?
|
DNA (Cytosine-5-)-Methyltransferases | 2 | 2008 | 310 | 0.110 |
Why?
|
Disease Models, Animal | 2 | 2016 | 7222 | 0.110 |
Why?
|
United States Food and Drug Administration | 1 | 2014 | 332 | 0.110 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2019 | 1331 | 0.110 |
Why?
|
Adenosine Kinase | 2 | 2002 | 7 | 0.110 |
Why?
|
Protein Subunits | 1 | 2013 | 274 | 0.110 |
Why?
|
Boron Compounds | 1 | 2012 | 59 | 0.110 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2017 | 10035 | 0.110 |
Why?
|
Mechlorethamine | 1 | 2011 | 51 | 0.100 |
Why?
|
Adenocarcinoma | 1 | 2010 | 7789 | 0.100 |
Why?
|
Reproducibility of Results | 4 | 2014 | 6009 | 0.100 |
Why?
|
Leukemia, Experimental | 2 | 2006 | 78 | 0.100 |
Why?
|
Leukemic Infiltration | 1 | 2011 | 72 | 0.100 |
Why?
|
Gene Knockout Techniques | 1 | 2012 | 276 | 0.100 |
Why?
|
Transfection | 4 | 2021 | 2944 | 0.100 |
Why?
|
Thalidomide | 1 | 2015 | 569 | 0.100 |
Why?
|
Chemotaxis, Leukocyte | 1 | 2011 | 157 | 0.100 |
Why?
|
raf Kinases | 1 | 2011 | 81 | 0.100 |
Why?
|
Apoptosomes | 1 | 2011 | 12 | 0.100 |
Why?
|
5'-Nucleotidase | 1 | 2011 | 61 | 0.100 |
Why?
|
Ribosome Inactivating Proteins, Type 1 | 2 | 2010 | 21 | 0.100 |
Why?
|
Cytochromes c | 2 | 2011 | 118 | 0.100 |
Why?
|
Pharmacogenetics | 2 | 2013 | 260 | 0.090 |
Why?
|
Cyclophosphamide | 3 | 2021 | 3001 | 0.090 |
Why?
|
Oligomycins | 1 | 2010 | 9 | 0.090 |
Why?
|
Disease Progression | 2 | 2013 | 6682 | 0.090 |
Why?
|
Imatinib Mesylate | 2 | 2012 | 1665 | 0.090 |
Why?
|
Dexamethasone | 1 | 2015 | 1450 | 0.090 |
Why?
|
Toxins, Biological | 1 | 2010 | 51 | 0.090 |
Why?
|
Cell Movement | 1 | 2017 | 2466 | 0.090 |
Why?
|
Citric Acid Cycle | 1 | 2010 | 86 | 0.090 |
Why?
|
Lymphoma, Follicular | 1 | 2015 | 587 | 0.090 |
Why?
|
Cell Differentiation | 1 | 2020 | 4078 | 0.090 |
Why?
|
Neoplasm Staging | 4 | 2017 | 13658 | 0.090 |
Why?
|
Halogenation | 1 | 2009 | 14 | 0.090 |
Why?
|
Poly A | 1 | 2009 | 87 | 0.090 |
Why?
|
Cytokines | 1 | 2019 | 2809 | 0.090 |
Why?
|
Oxazines | 1 | 2009 | 43 | 0.090 |
Why?
|
Research Design | 1 | 2017 | 1544 | 0.090 |
Why?
|
DNA, Complementary | 2 | 2007 | 869 | 0.090 |
Why?
|
Age Factors | 2 | 2016 | 5377 | 0.090 |
Why?
|
Nitrendipine | 1 | 1988 | 3 | 0.090 |
Why?
|
Heat Shock Transcription Factors | 1 | 2009 | 51 | 0.090 |
Why?
|
Dactinomycin | 1 | 2009 | 145 | 0.090 |
Why?
|
Hydrolysis | 1 | 2009 | 227 | 0.080 |
Why?
|
Neoplasm Metastasis | 3 | 2012 | 5112 | 0.080 |
Why?
|
Multidrug Resistance-Associated Proteins | 1 | 2009 | 83 | 0.080 |
Why?
|
Amino Acid Chloromethyl Ketones | 1 | 2008 | 25 | 0.080 |
Why?
|
Apoptosis Inducing Factor | 1 | 2008 | 19 | 0.080 |
Why?
|
Up-Regulation | 3 | 2018 | 2450 | 0.080 |
Why?
|
Mitochondrial Membranes | 1 | 2008 | 58 | 0.080 |
Why?
|
Biological Transport, Active | 1 | 2008 | 131 | 0.080 |
Why?
|
Survival Rate | 8 | 2021 | 12221 | 0.080 |
Why?
|
Caspase Inhibitors | 1 | 2008 | 95 | 0.080 |
Why?
|
Cysteine Proteinase Inhibitors | 1 | 2008 | 94 | 0.080 |
Why?
|
Nimodipine | 1 | 1987 | 8 | 0.080 |
Why?
|
Molecular Mimicry | 1 | 2008 | 72 | 0.080 |
Why?
|
Combined Modality Therapy | 3 | 2017 | 8865 | 0.080 |
Why?
|
Calpain | 1 | 2008 | 64 | 0.080 |
Why?
|
Core Binding Factors | 1 | 2008 | 112 | 0.080 |
Why?
|
Biological Availability | 2 | 2002 | 214 | 0.080 |
Why?
|
Receptors, Opioid | 1 | 1987 | 35 | 0.080 |
Why?
|
Cattle | 1 | 2009 | 783 | 0.080 |
Why?
|
Dipeptides | 1 | 2008 | 91 | 0.080 |
Why?
|
Superoxides | 1 | 2008 | 211 | 0.080 |
Why?
|
RNA, Catalytic | 1 | 2007 | 37 | 0.080 |
Why?
|
Biosynthetic Pathways | 1 | 2007 | 46 | 0.080 |
Why?
|
Glucocorticoids | 2 | 2008 | 629 | 0.080 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2012 | 810 | 0.080 |
Why?
|
G2 Phase | 2 | 2002 | 206 | 0.080 |
Why?
|
HSP70 Heat-Shock Proteins | 1 | 2008 | 161 | 0.080 |
Why?
|
Pyrrolidines | 1 | 1987 | 113 | 0.080 |
Why?
|
Introns | 1 | 2008 | 432 | 0.080 |
Why?
|
Chromatin Immunoprecipitation | 1 | 2008 | 518 | 0.080 |
Why?
|
Acetylcysteine | 1 | 2008 | 143 | 0.080 |
Why?
|
Cyclin-Dependent Kinases | 1 | 2009 | 311 | 0.080 |
Why?
|
Leukemia, B-Cell | 2 | 1998 | 117 | 0.070 |
Why?
|
ATP-Binding Cassette Transporters | 1 | 2009 | 299 | 0.070 |
Why?
|
Dipyridamole | 2 | 2022 | 33 | 0.070 |
Why?
|
Esters | 2 | 2018 | 45 | 0.070 |
Why?
|
Models, Molecular | 2 | 2009 | 1732 | 0.070 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2012 | 973 | 0.070 |
Why?
|
Lymphatic Metastasis | 1 | 2016 | 4844 | 0.070 |
Why?
|
Ion Channels | 1 | 1987 | 212 | 0.070 |
Why?
|
RNA, Ribosomal | 2 | 2003 | 83 | 0.070 |
Why?
|
Cell-Free System | 2 | 2006 | 150 | 0.070 |
Why?
|
Nucleic Acid Synthesis Inhibitors | 2 | 2003 | 43 | 0.070 |
Why?
|
Marketing | 1 | 2006 | 18 | 0.070 |
Why?
|
Infant | 5 | 2018 | 13310 | 0.070 |
Why?
|
Mitoxantrone | 2 | 1996 | 216 | 0.070 |
Why?
|
Metformin | 1 | 2010 | 378 | 0.070 |
Why?
|
Leukocyte Count | 2 | 2004 | 684 | 0.070 |
Why?
|
Staurosporine | 1 | 2005 | 143 | 0.070 |
Why?
|
Breast Neoplasms | 2 | 2009 | 15694 | 0.070 |
Why?
|
Hypoglycemic Agents | 1 | 2010 | 586 | 0.070 |
Why?
|
Tumor Suppressor Proteins | 1 | 2013 | 1823 | 0.070 |
Why?
|
G1 Phase | 2 | 1999 | 285 | 0.070 |
Why?
|
Oncogenes | 1 | 2008 | 673 | 0.070 |
Why?
|
Cell Nucleolus | 2 | 1983 | 89 | 0.070 |
Why?
|
Case-Control Studies | 1 | 2015 | 6100 | 0.060 |
Why?
|
Disease-Free Survival | 5 | 2018 | 10001 | 0.060 |
Why?
|
Hypereosinophilic Syndrome | 1 | 2005 | 89 | 0.060 |
Why?
|
Spinal Cord | 1 | 1988 | 690 | 0.060 |
Why?
|
Cell Lineage | 1 | 2007 | 668 | 0.060 |
Why?
|
STAT3 Transcription Factor | 1 | 2011 | 1121 | 0.060 |
Why?
|
DNA Fragmentation | 2 | 2007 | 198 | 0.060 |
Why?
|
Tissue Distribution | 1 | 2006 | 875 | 0.060 |
Why?
|
Colony-Forming Units Assay | 1 | 2004 | 249 | 0.060 |
Why?
|
DCMP Deaminase | 2 | 1996 | 10 | 0.060 |
Why?
|
Models, Genetic | 1 | 2008 | 1113 | 0.060 |
Why?
|
Mitogen-Activated Protein Kinase 3 | 1 | 2005 | 259 | 0.060 |
Why?
|
Cricetinae | 2 | 1995 | 706 | 0.060 |
Why?
|
Lymphocyte Activation | 1 | 2009 | 1688 | 0.060 |
Why?
|
Leukemia, Promyelocytic, Acute | 1 | 2007 | 430 | 0.060 |
Why?
|
Lymphocyte Count | 2 | 2019 | 486 | 0.060 |
Why?
|
Guanosine Monophosphate | 1 | 2003 | 6 | 0.060 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 1 | 2005 | 280 | 0.060 |
Why?
|
Neutropenia | 2 | 2019 | 968 | 0.060 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 1 | 2005 | 334 | 0.060 |
Why?
|
Paecilomyces | 1 | 2003 | 8 | 0.060 |
Why?
|
Antigens, CD19 | 1 | 2006 | 577 | 0.060 |
Why?
|
Peritoneal Dialysis, Continuous Ambulatory | 1 | 2003 | 21 | 0.060 |
Why?
|
Deoxycytosine Nucleotides | 2 | 1994 | 32 | 0.060 |
Why?
|
Glucose | 1 | 2009 | 1248 | 0.060 |
Why?
|
Carcinoma, Renal Cell | 1 | 2015 | 2326 | 0.060 |
Why?
|
Quinaldines | 1 | 2022 | 1 | 0.060 |
Why?
|
Faculty | 1 | 2024 | 130 | 0.060 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2009 | 2508 | 0.060 |
Why?
|
Oligonucleotides | 1 | 2003 | 227 | 0.050 |
Why?
|
Structure-Activity Relationship | 2 | 2014 | 931 | 0.050 |
Why?
|
Fas Ligand Protein | 1 | 2003 | 150 | 0.050 |
Why?
|
Peritonitis | 1 | 2003 | 89 | 0.050 |
Why?
|
DNA Mutational Analysis | 1 | 2008 | 2283 | 0.050 |
Why?
|
Chlorambucil | 1 | 2002 | 26 | 0.050 |
Why?
|
Nucleoside Deaminases | 1 | 2002 | 33 | 0.050 |
Why?
|
Inosine | 1 | 2002 | 39 | 0.050 |
Why?
|
United States | 2 | 2024 | 15433 | 0.050 |
Why?
|
Adenosine Deaminase | 1 | 2002 | 94 | 0.050 |
Why?
|
Interleukin Receptor Common gamma Subunit | 1 | 2022 | 47 | 0.050 |
Why?
|
Phenotype | 3 | 2011 | 6295 | 0.050 |
Why?
|
Half-Life | 3 | 2004 | 259 | 0.050 |
Why?
|
fas Receptor | 1 | 2003 | 185 | 0.050 |
Why?
|
Sex Chromosomes | 1 | 1982 | 43 | 0.050 |
Why?
|
Antimalarials | 1 | 2002 | 55 | 0.050 |
Why?
|
Y Chromosome | 1 | 1982 | 77 | 0.050 |
Why?
|
Career Choice | 1 | 2024 | 232 | 0.050 |
Why?
|
Software | 1 | 2009 | 1321 | 0.050 |
Why?
|
Safety | 1 | 2003 | 465 | 0.050 |
Why?
|
Mentors | 1 | 2024 | 203 | 0.050 |
Why?
|
Neovascularization, Pathologic | 1 | 2008 | 1547 | 0.050 |
Why?
|
Kidney Neoplasms | 1 | 2015 | 3022 | 0.050 |
Why?
|
Fatigue | 2 | 2018 | 1239 | 0.050 |
Why?
|
Risk Factors | 3 | 2013 | 17523 | 0.050 |
Why?
|
Protozoan Proteins | 1 | 2002 | 114 | 0.050 |
Why?
|
Species Specificity | 1 | 2002 | 777 | 0.050 |
Why?
|
Spectrophotometry, Ultraviolet | 1 | 2000 | 71 | 0.050 |
Why?
|
Electrophoretic Mobility Shift Assay | 2 | 2011 | 191 | 0.050 |
Why?
|
Proteins | 2 | 2006 | 1963 | 0.050 |
Why?
|
Inflammation | 1 | 2010 | 2522 | 0.050 |
Why?
|
Aphidicolin | 1 | 1999 | 30 | 0.050 |
Why?
|
Genetic Therapy | 1 | 2007 | 1616 | 0.040 |
Why?
|
Leiomyosarcoma | 1 | 2001 | 223 | 0.040 |
Why?
|
Mice, Nude | 2 | 2019 | 4307 | 0.040 |
Why?
|
Linkage Disequilibrium | 2 | 2013 | 460 | 0.040 |
Why?
|
Gastrointestinal Neoplasms | 2 | 2003 | 600 | 0.040 |
Why?
|
Telomerase | 1 | 2003 | 525 | 0.040 |
Why?
|
Follow-Up Studies | 4 | 2021 | 14889 | 0.040 |
Why?
|
Calibration | 1 | 2000 | 337 | 0.040 |
Why?
|
Multicenter Studies as Topic | 2 | 1998 | 543 | 0.040 |
Why?
|
Poly(ADP-ribose) Polymerases | 3 | 2007 | 324 | 0.040 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2021 | 2232 | 0.040 |
Why?
|
Mycoses | 1 | 2003 | 386 | 0.040 |
Why?
|
Methylation | 2 | 2011 | 597 | 0.040 |
Why?
|
Glutaminase | 1 | 2019 | 47 | 0.040 |
Why?
|
Drosophila melanogaster | 2 | 1983 | 829 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 3 | 2018 | 6207 | 0.040 |
Why?
|
Virus Replication | 1 | 2022 | 709 | 0.040 |
Why?
|
Maximum Allowable Concentration | 1 | 1998 | 9 | 0.040 |
Why?
|
Leukemia, Erythroblastic, Acute | 1 | 1999 | 118 | 0.040 |
Why?
|
Myeloid-Derived Suppressor Cells | 1 | 2019 | 100 | 0.040 |
Why?
|
Transcription Factors | 2 | 2011 | 5270 | 0.040 |
Why?
|
Curriculum | 1 | 2024 | 860 | 0.040 |
Why?
|
Lymphoma, T-Cell, Cutaneous | 1 | 2001 | 294 | 0.040 |
Why?
|
Mice, Transgenic | 2 | 2019 | 4143 | 0.040 |
Why?
|
Membrane Glycoproteins | 1 | 2003 | 1073 | 0.040 |
Why?
|
Genomics | 1 | 2009 | 2738 | 0.040 |
Why?
|
Brain Neoplasms | 1 | 2015 | 4849 | 0.040 |
Why?
|
Sensitivity and Specificity | 2 | 2000 | 4971 | 0.040 |
Why?
|
DNA-Binding Proteins | 2 | 2009 | 4821 | 0.040 |
Why?
|
Templates, Genetic | 1 | 1997 | 86 | 0.040 |
Why?
|
Cytochrome P-450 CYP3A | 1 | 2018 | 83 | 0.040 |
Why?
|
Base Composition | 1 | 1997 | 92 | 0.040 |
Why?
|
Rats, Sprague-Dawley | 1 | 2002 | 2063 | 0.040 |
Why?
|
Feasibility Studies | 1 | 2022 | 2292 | 0.040 |
Why?
|
Deoxycytidine Monophosphate | 1 | 1996 | 5 | 0.040 |
Why?
|
Biomimetics | 1 | 2017 | 33 | 0.040 |
Why?
|
Neoplasm Invasiveness | 1 | 2005 | 3981 | 0.040 |
Why?
|
Chemistry Techniques, Synthetic | 1 | 2016 | 13 | 0.040 |
Why?
|
Phosphoric Monoester Hydrolases | 2 | 2010 | 243 | 0.040 |
Why?
|
Cohort Studies | 2 | 2011 | 9244 | 0.040 |
Why?
|
Kidney Failure, Chronic | 2 | 2003 | 960 | 0.040 |
Why?
|
Exodeoxyribonucleases | 1 | 1996 | 104 | 0.040 |
Why?
|
Survival Analysis | 3 | 2012 | 9180 | 0.040 |
Why?
|
Homeostasis | 1 | 2021 | 950 | 0.030 |
Why?
|
Cell Adhesion | 2 | 2009 | 1008 | 0.030 |
Why?
|
Antibodies, Monoclonal, Humanized | 2 | 2021 | 3251 | 0.030 |
Why?
|
Peptide Chain Elongation, Translational | 1 | 1995 | 6 | 0.030 |
Why?
|
Induction Chemotherapy | 1 | 2019 | 669 | 0.030 |
Why?
|
Drug Evaluation | 3 | 1993 | 425 | 0.030 |
Why?
|
DNA Topoisomerases, Type II | 1 | 1996 | 116 | 0.030 |
Why?
|
Cell Membrane | 2 | 2009 | 850 | 0.030 |
Why?
|
DNA-Directed DNA Polymerase | 1 | 1996 | 182 | 0.030 |
Why?
|
Cytidine Deaminase | 1 | 1995 | 83 | 0.030 |
Why?
|
Mice, Inbred C57BL | 2 | 2019 | 6942 | 0.030 |
Why?
|
Daunorubicin | 2 | 2009 | 301 | 0.030 |
Why?
|
Antiviral Agents | 1 | 2022 | 1230 | 0.030 |
Why?
|
CHO Cells | 1 | 1995 | 311 | 0.030 |
Why?
|
Mice, Inbred BALB C | 1 | 2019 | 2314 | 0.030 |
Why?
|
Genome, Human | 1 | 2003 | 1869 | 0.030 |
Why?
|
Biological Transport | 2 | 2007 | 597 | 0.030 |
Why?
|
JNK Mitogen-Activated Protein Kinases | 2 | 2005 | 301 | 0.030 |
Why?
|
Drug Discovery | 1 | 2017 | 324 | 0.030 |
Why?
|
Etoposide | 2 | 2009 | 870 | 0.030 |
Why?
|
HapMap Project | 1 | 2013 | 19 | 0.030 |
Why?
|
Neoplasm, Residual | 1 | 2019 | 1656 | 0.030 |
Why?
|
Macrophages | 1 | 2019 | 1304 | 0.030 |
Why?
|
Hemodialysis Solutions | 1 | 1992 | 6 | 0.030 |
Why?
|
Hodgkin Disease | 1 | 2001 | 1429 | 0.030 |
Why?
|
Protein Array Analysis | 1 | 2015 | 501 | 0.030 |
Why?
|
Hypophosphatemia | 1 | 1992 | 26 | 0.030 |
Why?
|
B7-H1 Antigen | 1 | 2019 | 1022 | 0.030 |
Why?
|
Pentose Phosphate Pathway | 1 | 2012 | 69 | 0.030 |
Why?
|
Phosphorus | 1 | 1992 | 65 | 0.030 |
Why?
|
Intracellular Fluid | 1 | 1992 | 45 | 0.030 |
Why?
|
Metaphase | 1 | 1992 | 107 | 0.030 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2019 | 1586 | 0.030 |
Why?
|
Ultrafiltration | 1 | 1991 | 22 | 0.030 |
Why?
|
Dialysis Solutions | 1 | 1991 | 10 | 0.030 |
Why?
|
Sterilization | 1 | 1991 | 13 | 0.030 |
Why?
|
Rituximab | 1 | 2017 | 1528 | 0.030 |
Why?
|
Atrial Fibrillation | 1 | 2019 | 719 | 0.030 |
Why?
|
Drug Interactions | 2 | 1992 | 553 | 0.030 |
Why?
|
Mice, Inbred C3H | 1 | 2011 | 385 | 0.030 |
Why?
|
Bicarbonates | 1 | 1991 | 130 | 0.020 |
Why?
|
Aminoglycosides | 1 | 2012 | 220 | 0.020 |
Why?
|
ErbB Receptors | 2 | 2012 | 2295 | 0.020 |
Why?
|
Deamination | 1 | 1990 | 13 | 0.020 |
Why?
|
Peptide Fragments | 1 | 2017 | 1271 | 0.020 |
Why?
|
Tumor Stem Cell Assay | 1 | 1991 | 231 | 0.020 |
Why?
|
RNA, Small Nuclear | 1 | 2010 | 57 | 0.020 |
Why?
|
Injections, Intravenous | 1 | 2011 | 573 | 0.020 |
Why?
|
Immunosuppressive Agents | 1 | 1996 | 1375 | 0.020 |
Why?
|
Luciferases | 1 | 2011 | 445 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2012 | 1053 | 0.020 |
Why?
|
Glucose Transporter Type 4 | 1 | 2009 | 26 | 0.020 |
Why?
|
I-kappa B Proteins | 1 | 2010 | 170 | 0.020 |
Why?
|
Phosphotransferases | 1 | 1989 | 84 | 0.020 |
Why?
|
Mutagens | 1 | 1990 | 187 | 0.020 |
Why?
|
Chloroquine | 1 | 2009 | 53 | 0.020 |
Why?
|
In Situ Nick-End Labeling | 1 | 2010 | 448 | 0.020 |
Why?
|
Glucose Transporter Type 1 | 1 | 2009 | 61 | 0.020 |
Why?
|
Syk Kinase | 1 | 2009 | 56 | 0.020 |
Why?
|
LLC-PK1 Cells | 1 | 2009 | 9 | 0.020 |
Why?
|
Peritoneal Dialysis | 1 | 1991 | 125 | 0.020 |
Why?
|
Quinacrine | 1 | 1988 | 7 | 0.020 |
Why?
|
3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester | 1 | 1988 | 8 | 0.020 |
Why?
|
Trifluoperazine | 1 | 1988 | 8 | 0.020 |
Why?
|
Receptors, Chemokine | 1 | 2009 | 114 | 0.020 |
Why?
|
Nifedipine | 1 | 1988 | 25 | 0.020 |
Why?
|
Verapamil | 1 | 1988 | 78 | 0.020 |
Why?
|
Genetic Association Studies | 1 | 2013 | 1084 | 0.020 |
Why?
|
Rats, Inbred Strains | 1 | 1988 | 410 | 0.020 |
Why?
|
Pain | 1 | 2017 | 1658 | 0.020 |
Why?
|
Asparaginase | 1 | 2009 | 184 | 0.020 |
Why?
|
Benzomorphans | 1 | 1987 | 1 | 0.020 |
Why?
|
3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer | 1 | 1987 | 2 | 0.020 |
Why?
|
Probability | 1 | 2010 | 866 | 0.020 |
Why?
|
Dioxolanes | 1 | 2008 | 41 | 0.020 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 1 | 2013 | 598 | 0.020 |
Why?
|
Receptors, Opioid, kappa | 1 | 1987 | 31 | 0.020 |
Why?
|
Binding, Competitive | 1 | 1987 | 300 | 0.020 |
Why?
|
Fibronectins | 1 | 2008 | 197 | 0.020 |
Why?
|
Brain Chemistry | 1 | 1987 | 145 | 0.020 |
Why?
|
Exons | 1 | 2011 | 1328 | 0.020 |
Why?
|
Biometry | 1 | 2009 | 241 | 0.020 |
Why?
|
Hypertension | 1 | 2017 | 1503 | 0.020 |
Why?
|
Plasma Cells | 1 | 2008 | 192 | 0.020 |
Why?
|
Cytosine | 1 | 2008 | 141 | 0.020 |
Why?
|
Cytoplasm | 1 | 2009 | 652 | 0.020 |
Why?
|
Microscopy, Fluorescence | 1 | 2009 | 769 | 0.020 |
Why?
|
Protein Structure, Quaternary | 1 | 2006 | 138 | 0.020 |
Why?
|
Cell Adhesion Molecules | 1 | 2009 | 577 | 0.020 |
Why?
|
Down Syndrome | 1 | 2009 | 226 | 0.020 |
Why?
|
Pharmacokinetics | 1 | 2005 | 42 | 0.020 |
Why?
|
Morphine | 1 | 1987 | 308 | 0.020 |
Why?
|
Immunotoxins | 1 | 2006 | 117 | 0.020 |
Why?
|
Oncogene Protein v-akt | 1 | 2005 | 101 | 0.020 |
Why?
|
India | 1 | 2006 | 301 | 0.020 |
Why?
|
Liver Neoplasms | 1 | 2002 | 4557 | 0.020 |
Why?
|
Risk Assessment | 2 | 2010 | 6869 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2013 | 2594 | 0.020 |
Why?
|
I-kappa B Kinase | 1 | 2006 | 250 | 0.020 |
Why?
|
Renal Dialysis | 1 | 1992 | 945 | 0.020 |
Why?
|
Protein Processing, Post-Translational | 1 | 2009 | 803 | 0.020 |
Why?
|
Checkpoint Kinase 1 | 1 | 2005 | 174 | 0.020 |
Why?
|
Polyphosphates | 1 | 2004 | 13 | 0.020 |
Why?
|
Metabolic Clearance Rate | 1 | 2004 | 231 | 0.020 |
Why?
|
Congresses as Topic | 1 | 2006 | 298 | 0.020 |
Why?
|
Protein Isoforms | 1 | 2006 | 842 | 0.020 |
Why?
|
Neoadjuvant Therapy | 1 | 2017 | 4975 | 0.020 |
Why?
|
Lysine | 1 | 2006 | 422 | 0.010 |
Why?
|
Multiprotein Complexes | 1 | 2006 | 395 | 0.010 |
Why?
|
Tritium | 1 | 2003 | 200 | 0.010 |
Why?
|
Drug Tolerance | 1 | 2003 | 114 | 0.010 |
Why?
|
NF-kappa B | 1 | 2010 | 1549 | 0.010 |
Why?
|
Annexin A5 | 1 | 2002 | 72 | 0.010 |
Why?
|
Genetic Variation | 1 | 2011 | 2086 | 0.010 |
Why?
|
Karyotyping | 1 | 2004 | 1022 | 0.010 |
Why?
|
Flucytosine | 1 | 2002 | 30 | 0.010 |
Why?
|
Cytosine Deaminase | 1 | 2002 | 39 | 0.010 |
Why?
|
Caspase 8 | 1 | 2002 | 145 | 0.010 |
Why?
|
Lymphoproliferative Disorders | 1 | 2005 | 366 | 0.010 |
Why?
|
Pupa | 1 | 1982 | 22 | 0.010 |
Why?
|
Ovum | 1 | 1982 | 54 | 0.010 |
Why?
|
Stem Cells | 1 | 2009 | 1213 | 0.010 |
Why?
|
Binding Sites | 1 | 2006 | 2171 | 0.010 |
Why?
|
DNA-Directed RNA Polymerases | 1 | 2002 | 97 | 0.010 |
Why?
|
Genes, Lethal | 1 | 1982 | 120 | 0.010 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 1 | 2002 | 568 | 0.010 |
Why?
|
Membrane Potentials | 1 | 2002 | 424 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2008 | 4298 | 0.010 |
Why?
|
Larva | 1 | 1982 | 274 | 0.010 |
Why?
|
Nucleic Acid Hybridization | 1 | 1982 | 542 | 0.010 |
Why?
|
Drug Combinations | 1 | 2002 | 621 | 0.010 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2006 | 1538 | 0.010 |
Why?
|
Phosphates | 1 | 2001 | 187 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2009 | 4988 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2010 | 4320 | 0.010 |
Why?
|
Telomere | 1 | 2003 | 505 | 0.010 |
Why?
|
Computer Simulation | 1 | 2004 | 1529 | 0.010 |
Why?
|
Interleukin-6 | 1 | 2002 | 1038 | 0.010 |
Why?
|
DNA Methylation | 1 | 2006 | 2669 | 0.010 |
Why?
|
Prospective Studies | 1 | 2010 | 12873 | 0.010 |
Why?
|
Brain | 1 | 1988 | 4113 | 0.010 |
Why?
|
Soft Tissue Neoplasms | 1 | 2001 | 882 | 0.010 |
Why?
|
Alkylating Agents | 1 | 1994 | 78 | 0.010 |
Why?
|
Conjunctivitis | 1 | 1993 | 31 | 0.010 |
Why?
|
Liver | 1 | 2003 | 2961 | 0.010 |
Why?
|
Cisplatin | 1 | 1999 | 2432 | 0.010 |
Why?
|
Micropore Filters | 1 | 1991 | 10 | 0.010 |
Why?
|
Bone Marrow Diseases | 1 | 1993 | 177 | 0.010 |
Why?
|
Nylons | 1 | 1991 | 19 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2003 | 7548 | 0.010 |
Why?
|
Radiation-Sensitizing Agents | 1 | 1994 | 363 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2003 | 4053 | 0.010 |
Why?
|
Sarcoma | 1 | 2001 | 1725 | 0.010 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2009 | 6550 | 0.010 |
Why?
|
Pancreatitis | 1 | 1993 | 267 | 0.010 |
Why?
|
Adrenal Cortex Hormones | 1 | 1994 | 544 | 0.010 |
Why?
|
Colitis | 1 | 1993 | 340 | 0.010 |
Why?
|
Peripheral Nervous System Diseases | 1 | 1993 | 393 | 0.010 |
Why?
|
Bone Marrow Transplantation | 1 | 1993 | 1581 | 0.000 |
Why?
|
DNA Restriction Enzymes | 1 | 1983 | 117 | 0.000 |
Why?
|
X Chromosome | 1 | 1983 | 339 | 0.000 |
Why?
|
Repetitive Sequences, Nucleic Acid | 1 | 1983 | 362 | 0.000 |
Why?
|
Genes | 1 | 1983 | 491 | 0.000 |
Why?
|